Welcome to Dividend.com
Please help us personalize your experience.
Select the one that best describes you
Continue to site >
Trending ETFs

SPDR® S&P Biotech ETF

etf
XBI
Dividend policy
Active
Price as of:
$136.68 +0.85 +0%
primary theme
Health Care Sector Equity
XBI (ETF)

SPDR® S&P Biotech ETF

Dividend policy
Active
Price as of:
$136.68 +0.85 +0%
primary theme
Health Care Sector Equity
XBI (ETF)
SPDR® S&P Biotech ETF
Dividend policy
Active
Price as of:
$136.68 +0.85 +0%
primary theme
Health Care Sector Equity

XBI - Snapshot

Vitals

  • YTD Return -2.9%
  • 3 Yr Annualized Return 10.3%
  • 5 Yr Annualized Return 17.3%
  • Net Assets $6.76 B
  • Holdings in Top 10 9.0%

52 WEEK LOW AND HIGH

$135.83
$103.87
$173.99

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.35%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 66.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) N/A
  • IRA N/A

Fund Classification

  • Primary Theme Health Care Sector Equity
  • Fund Type Exchange Traded Fund
  • Investment Style Health

Compare XBI to Popular Health Care Sector Equity Funds

Overview

Next Dividend

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Dividend.com Ratings*

$122.03

-0.49%

$17.26 B

1.19%

$1.45

blocked
blocked
blocked

9.04%

0.10%

Compare XBI to Popular Health Care Sector Equity ETFs

Overview

Next Dividend

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Dividend.com Ratings*

$124.66

+0.09%

$27.65 B

1.37%

$1.70

blocked
blocked
blocked

9.89%

0.13%

$244.31

+0.11%

$17.26 B

1.19%

$2.90

blocked
blocked
blocked

9.20%

0.10%

$162.11

-0.67%

$10.16 B

0.24%

$0.39

blocked
blocked
blocked

6.83%

0.45%

$345.80

+0.06%

$7.83 B

0.24%

$0.81

blocked
blocked
blocked

6.18%

0.41%

$136.68

+0.63%

$6.76 B

0.24%

$0.32

blocked
blocked
blocked

-2.91%

0.35%

XBI - Profile

Distributions

  • YTD Total Return -2.9%
  • 3 Yr Annualized Total Return 10.3%
  • 5 Yr Annualized Total Return 17.3%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.01%
DIVIDENDS
  • Dividend Yield 0.1%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    SPDR® S&P Biotech ETF
  • Fund Family Name
    SPDR State Street Global Advisors
  • Inception Date
    Jan 31, 2006
  • Shares Outstanding
    52875000
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Michael Feehily

Fund Description

In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").


XBI - Performance

Return Ranking - Trailing

Period XBI Return Category Return Low Category Return High Rank in Category (%)
YTD -2.9% -12.2% 26.8% 93.02%
1 Yr 23.7% -1.4% 110.6% 27.38%
3 Yr 10.3%* 3.2% 43.8% 85.14%
5 Yr 17.3%* 3.7% 37.4% 12.77%
10 Yr 18.1%* 8.4% 18.8% 4.88%

* Annualized

Return Ranking - Calendar

Period XBI Return Category Return Low Category Return High Rank in Category (%)
2020 48.0% -13.6% 178.2% 6.83%
2019 32.6% 3.8% 63.8% 8.97%
2018 -15.5% -49.7% 21.5% 86.13%
2017 43.4% -59.8% 54.4% 5.19%
2016 -15.7% -36.6% 11.6% 53.13%

Total Return Ranking - Trailing

Period XBI Return Category Return Low Category Return High Rank in Category (%)
YTD -2.9% -12.2% 28.1% 93.02%
1 Yr 23.7% -1.4% 110.6% 26.19%
3 Yr 10.3%* 3.2% 43.8% 82.43%
5 Yr 17.3%* 3.7% 37.4% 12.77%
10 Yr 18.1%* 8.4% 18.8% 4.88%

* Annualized

Total Return Ranking - Calendar

Period XBI Return Category Return Low Category Return High Rank in Category (%)
2020 48.0% -13.6% 178.2% 6.83%
2019 32.6% 3.8% 63.8% 8.97%
2018 -15.5% -25.3% 22.2% 87.59%
2017 43.4% -10.8% 54.4% 5.93%
2016 -15.7% -36.6% 11.6% 64.84%

XBI - Holdings

Concentration Analysis

XBI Category Low Category High XBI % Rank
Net Assets 6.76 B 6.68 M 49.7 B 14.45%
Number of Holdings 193 25 483 6.94%
Net Assets in Top 10 615 M 1.53 M 19.3 B 38.73%
Weighting of Top 10 8.95% 8.9% 78.2% 100.00%

Top 10 Holdings

  1. Arcturus Therapeutics Holdings Inc 1.92%
  2. Immunomedics Inc 1.87%
  3. Aimmune Therapeutics Inc 1.78%
  4. Vir Biotechnology Inc 1.68%
  5. Momenta Pharmaceuticals Inc 1.66%
  6. Exact Sciences Corp 1.55%
  7. Natera Inc 1.54%
  8. Arrowhead Pharmaceuticals Inc 1.52%
  9. Blueprint Medicines Corp 1.47%
  10. Mirati Therapeutics Inc 1.45%

Asset Allocation

Weighting Return Low Return High XBI % Rank
Stocks
99.90% 82.66% 105.23% 19.65%
Cash
0.11% -0.13% 17.34% 72.25%
Preferred Stocks
0.00% 0.00% 5.58% 80.92%
Other
0.00% -26.63% 8.98% 80.92%
Convertible Bonds
0.00% 0.00% 0.02% 77.46%
Bonds
0.00% 0.00% 18.37% 79.19%

Stock Sector Breakdown

Weighting Return Low Return High XBI % Rank
Healthcare
100.00% 63.71% 100.00% 26.01%
Utilities
0.00% 0.00% 0.00% 76.88%
Technology
0.00% 0.00% 19.82% 80.92%
Real Estate
0.00% 0.00% 6.18% 79.77%
Industrials
0.00% 0.00% 6.41% 79.19%
Financial Services
0.00% 0.00% 3.21% 89.02%
Energy
0.00% 0.00% 0.00% 76.88%
Communication Services
0.00% 0.00% 8.10% 79.19%
Consumer Defense
0.00% 0.00% 29.47% 77.46%
Consumer Cyclical
0.00% 0.00% 14.16% 79.77%
Basic Materials
0.00% 0.00% 3.71% 83.82%

Stock Geographic Breakdown

Weighting Return Low Return High XBI % Rank
US
98.89% 58.55% 101.51% 10.98%
Non US
1.01% 0.00% 40.32% 87.86%

XBI - Expenses

Operational Fees

XBI Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.35% 0.08% 7.05% 92.90%
Management Fee 0.35% 0.00% 1.25% 9.14%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

XBI Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

XBI Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

XBI Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 66.00% 3.00% 256.00% 72.22%

XBI - Distributions

Dividend Yield Analysis

XBI Category Low Category High XBI % Rank
Dividend Yield 0.08% 0.00% 0.95% 12.57%

Dividend Distribution Analysis

XBI Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annually Quarterly Annually

Net Income Ratio Analysis

XBI Category Low Category High XBI % Rank
Net Income Ratio 0.01% -2.54% 1.74% 47.06%

Capital Gain Distribution Analysis

XBI Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

XBI - Fund Manager Analysis

Managers

Michael Feehily


Start Date

Tenure

Tenure Rank

Oct 31, 2011

9.59

9.6%

Mr. Feehily, CFA, is a Managing Director of SSGA and the Adviser and Co-Head of Passive Equity Strategies in North America in the Global Equity Beta Solutions Group. In this capacity, Mr. Feehily has oversight of the North American Passive Equity teams in Boston and Montreal. In addition, Mr. Feehily is a member of the Senior Management Group. Mr. Feehily rejoined SSgA in 2010 after spending the previous four years at State Street Global Markets LLC where he helped to build the Exposure Solutions business.

Karl Schneider


Start Date

Tenure

Tenure Rank

Oct 31, 2014

6.59

6.6%

Karl Schneider, CAIA, is a Vice President of SSGA and SSGA FM, and Head of U.S. Equity Strategies for GEBS, where in addition to overseeing the management of the U.S. equity index strategies, he also serves as a portfolio manager for a number of the group's passive equity portfolios. Previously within GEBS, he served as a portfolio manager and product specialist for synthetic beta strategies, including commodities, buy/write, and hedge fund replication. Prior to joining GEBS, Mr. Schneider worked as a portfolio manager in SSGA's Currency Management Group, managing both active currency selection and traditional passive hedging overlay portfolios. He joined SSGA in 1996. Mr. Schneider holds a BS in finance and investments from Babson College and an MS in finance from Boston College. He has earned the Chartered Alternative Investment Analyst designation. Mr. Schneider is a member of the CAIA Association.

Raymond Donofrio


Start Date

Tenure

Tenure Rank

Jan 03, 2017

4.41

4.4%

Raymond Donofrio is a Vice President of SSGA and a Senior Portfolio Manager in the Global Equity Beta Solutions Group. Mr. Donofrio is currently responsible for managing various equity index funds, with both domestic and international strategies. Prior to his current role, Mr. Donofrio was an analyst for SSGA’s Strategy and Research Group within the Global ETF Group. He began his career as an associate within the Investment Operations team at SSGA, where he supported the portfolio managers of the Global Equity Beta Solutions Group, mainly focusing on international strategies. Mr. Donofrio received his Bachelor of Science in Financial Services from Bryant University and his Master of Business Administration with a concentration in Finance from Boston University’s Questrom School of Business.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.04 23.72 7.22 21.1